RxDoctor Payments Data

Peter Sylves, DO

Internal Medicine · Butler, PANPI 1952350407

Payments from drug & device makers

$7,064in general payments, 2019–2025

Across 447 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$841
  • AbbVie$767
  • Lilly USA, LLC$449
  • Boehringer Ingelheim$381
  • Amgen$355
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,02899%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,064 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,649
Medicare patients
185
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin155$186,753
OzempicSemaglutide111$123,271
EliquisApixaban123$108,646
FarxigaDapagliflozin Propanediol100$102,596
TrulicityDulaglutide51$63,684
RybelsusSemaglutide27$53,130
JanuviaSitagliptin Phosphate38$41,491
XifaxanRifaximin13$39,004
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$36,528
XareltoRivaroxaban32$30,873
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$28,086
MyrbetriqMirabegron29$23,636
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$23,117
ProliaDenosumab11$18,922
Bydureon BciseExenatide Microspheres11$16,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$381$206,483189 claims
Novo NordiskOzempic, Rybelsus$1,134$176,401138 claims
AstraZenecaFarxiga, Breztri Aerosphere$323$130,682146 claims
PfizerEliquis$265$108,646123 claims
Lilly USA, LLCTrulicity$449$63,68451 claims
GSKTrelegy Ellipta, Anoro Ellipta$841$59,64589 claims
MerckJanuvia, Janumet Xr$285$57,42159 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$168$39,00413 claims
Johnson & JohnsonXarelto$65$30,87332 claims
Astellas Pharma US IncMyrbetriq$180$23,63629 claims
AbbVieCreon, Synthroid$767$19,55078 claims
AmgenProlia$355$18,92211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →